Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Feb;52(2):635-7.
doi: 10.1128/JCM.02517-13. Epub 2013 Nov 27.

GeneXpert MTB/RIF version G4 for identification of rifampin-resistant tuberculosis in a programmatic setting

Muhammad Osman  1 , John A Simpson, Judy Caldwell, Marlein Bosman, Mark P Nicol
Affiliations

GeneXpert MTB/RIF version G4 for identification of rifampin-resistant tuberculosis in a programmatic setting

Muhammad Osman et al. J Clin Microbiol. 2014 Feb.

Abstract

A recent Cochrane review estimated GeneXpert MTB/RIF specificity for rifampin resistance as 98% (95% confidence interval [CI], 97 to 99), based on results from earlier test versions. The measured positive predictive value of the new generation test from programmatic implementation in Cape Town, South Africa, was 99.5% (95% CI, 98.5 to 100), confirming excellent specificity.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Outcome of diagnostic testing for patients with rifampin resistance identified by Xpert MTB/RIF. GXP, GeneXpert MTB/RIF; Rif, rifampin; MTB, Mycobacterium tuberculosis; INH, isoniazid; R, resistant; S, susceptible.
See this image and copyright information in PMC

References

    1. World Health Organization 2011. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. World Health Organization, Geneva, Switzerland - PubMed
    1. World Health Organization WHO monitoring of Xpert MTB/RIF roll-out. http://www.who.int/tb/laboratory/mtbrifrollout/en/index.html Accessed 26 July 2013
    1. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. 2011. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377:1495–1505. 10.1016/S0140-6736(11)60438-8 - DOI - PMC - PubMed
    1. Williamson DA, Basu I, Bower J, Freeman JT, Henderson G, Roberts SA. 2012. An evaluation of the Xpert MTB/RIF assay and detection of false-positive rifampicin resistance in Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis. 74:207–209. 10.1016/j.diagmicrobio.2012.06.013 - DOI - PubMed
    1. Foundation for Innovative New Diagnostics 2011. FIND report: performance of Xpert MTB/RIF version G4 assay. FIND, Geneva, Switzerland

Publication types

MeSH terms